Evolus (EOLS) closed at $6.81 on November 6, 2026, up 0.1% from the previous close, on volume of 1,501,273 shares (30-day average 749,593).
Data as of November 6, 2026.
6-Nov-2026
Evolus (EOLS) Gets a Buy from Leerink Partners
TipRanks (Thu, 5-Nov 9:28 AM ET)
Stifel Nicolaus Remains a Buy on Evolus (EOLS)
TipRanks (Thu, 5-Nov 7:57 AM ET)
H.C. Wainwright Sticks to Their Buy Rating for Evolus (EOLS)
TipRanks (Thu, 5-Nov 7:26 AM ET)
Evolus GAAP EPS of -$0.19 misses by $0.02, revenue of $77.9M beats by $0.32M
Seeking Alpha News (Wed, 4-Nov 4:28 PM ET)
Business Wire (Wed, 4-Nov 4:05 PM ET)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
Globe Newswire (Tue, 3-Nov 5:58 PM ET)
Evolus Q3 2026 Earnings Preview
Seeking Alpha News (Tue, 3-Nov 5:35 PM ET)
Evolus to Participate in Upcoming Investor Conferences in New York and London
Business Wire (Wed, 28-Oct 8:30 AM ET)
Evolus to Report Third Quarter Financial Results on November 4, 2026
Business Wire (Wed, 21-Oct 8:30 AM ET)
Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program
Business Wire (Wed, 14-Oct 8:30 AM ET)
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
Evolus trades on the NASDAQ stock market under the symbol EOLS.
As of November 6, 2026, EOLS stock price climbed to $6.80 with 1,501,273 million shares trading.
EOLS has a beta of 1.89, meaning it tends to be more sensitive to market movements. EOLS has a correlation of 0.13 to the broad based SPY ETF.
EOLS has a market cap of $449.47 million. This is considered a Small Cap stock.
Last quarter Evolus reported $78 million in Revenue and -$.19 earnings per share. This beat revenue expectation by $520,136 and missed earnings estimates by -$.11.
In the last 3 years, EOLS traded as high as $17.82 and as low as $3.86.
The top ETF exchange traded funds that EOLS belongs to (by Net Assets): VTI, IWM, VXF, IWO, XPH.
EOLS has underperformed the market in the last year with a return of -5.2%, while the SPY ETF gained +10.8%. In the last 3 month period, EOLS fell short of the market, returning -8.2%, while SPY returned -4.1%. However, in the most recent 2 weeks EOLS has outperformed the stock market by returning -2.9%, while SPY returned -3.2%.
EOLS support price is $6.55 and resistance is $7.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EOLS shares will trade within this expected range on the day.